Optimizing the Management of Parkinson’s Disease: Considerations for Treating Early Disease and Minimizing Motor Complications in Advanced Disease

Program Description & Educational Objectives

In this two-part activity, an expert panel discusses the clinical challenges associated with the management of Parkinson’s disease. Topics addressed in this activity include the management of motor symptoms in patients with early Parkinson's disease and potential strategies to minimize motor complications in the advanced disease setting. Recent data on available and emerging therapies for patients with Parkinson's disease are also discussed.

Upon completion of this activity, participants will be able to:

• Apply recent efficacy and safety data related to the symptomatic treatment of early Parkinson's disease
• Employ adjunctive treatment strategies for the management of motor complications in patients with advanced Parkinson's disease

Target Audience

This activity has been designed to meet the educational needs of neurologists, pharmacists, and other healthcare professionals involved in the management of Parkinson’s disease.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: January 18, 2012 - January 17, 2013
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Ramon L. Rodriguez, MD
Clinical Associate Professor of Neurology
Director, Movement Disorders Clinic
Director, Tyler’s Hope Center for Comprehensive Dystonia Care
UF Center for Movement Disorders & Neurorestoration
University of Florida College of Medicine
Gainesville, Florida

Ramon L. Rodriguez, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Allergan, Inc.; Lundbeck, Inc.; Merz Pharmaceuticals, LLC; and Teva Pharmaceuticals USA.

Interviewees

Michael S. Okun, MD
Administrative Director
UF Center for Movement Disorders & Neurorestoration
Adelaide Lackner Associate Professor of Neurology
University of Florida College of Medicine
Gainesville Florida

Michael S. Okun, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for the National Parkinson Foundation.

Grant/Research Support from National Institutes of Health; The Michael J. Fox Foundation for Parkinson's Research; and The Parkinson Alliance.

Advisory Board for the National Parkinson Foundation; Tourette Syndrome Association, Inc.; and Tyler's Hope for a Dystonia Cure Inc.

Other Financial or Material Support from Vanderbilt University Medical Center and VSF for CME Courses.

Hubert H. Fernandez, MD
Professor of Medicine (Neurology)
Cleveland Clinic Lerner College of Medicine
Head, Section of Movement Disorders
Center for Neurological Restoration
Cleveland Clinic
Cleveland, Ohio

Hubert H. Fernandez, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for IPSEN; Merz Pharmaceuticals, LLC; and United BioSource Corporation. The Cleveland Clinic also has contracts with Abbott Laboratories; EMD Serono, Inc.; and Merz Pharmaceuticals, LLC for his role as a member of the Global Steering Committee at Safinamide and LCID studies; and Head Principal Investigator in the Xeomin Registry Study. Dr. Fernandez does not receive any personal compensation for these roles.

Grant/Research Support from Abbott Laboratories; ACADIA Pharmaceuticals Inc.; Biotie Therapies Corp.; EMD Serono, Inc.; Huntington Study Group; IPSEN; Merz Pharmaceuticals, LLC; National Institutes of Health; National Institute of Neurological Disorders and Stroke; National Parkinson Foundation; Novartis AG; Parkinson Study Group; Teva Pharmaceuticals USA; The Michael J. Fox Foundation; and The Movement Disorder Society.

Honoraria from IPSEN; Merz Pharmaceuticals, LLC; and US WorldMeds.

Other Financial or Material Support from Demos Medical Publishing; Manson Publishing; Springer Publishing Company in the form of royalty payments for serving as a book author. Dr. Fernandez has received a stipend from the Movement Disorders Society for serving as a Medical Editor of the MDS website.

CME Reviewer

James M. Smith, MD
Clinical Assistant Professor and Program Director
Department of Internal Medicine
University of Florida College of Medicine
Gainesville, Florida

James M. Smith, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

Content Director

Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education

Kirk A. Tacka, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Participants will earn 0.5 contact hours or 0.05 CEUs for completing the program. Participants must attend the entire program and complete an evaluation form. Statements of Credit will be provided to participants within 4 weeks of the end of the program. UAN(s): 0453-9999-11-196-P (K) .

This CME/CPE activity is jointly sponsored by the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education; the activity is also co-provided by Amedco.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.